Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI(R)” for the Treatment of Early Alzheimer’s Disease in Japan
Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the initiation of treatment for this progressive, relentless disease TOKYO and CAMBRIDGE,…
bubmagNovember 28, 2025